40+ years of excellence in custom synthesis and bioconjugation services.
Calculators, design tools, and educational content to support your research.
Custom multiple antigen peptide synthesis for MAP2, MAP4, MAP8 and advanced lysine-core architectures, including carrier-free peptide immunogens, labeled MAP reagents and multivalent constructs with fit-for-purpose purification and QC.
A Multiple Antigen Peptide (MAP) is a branched, lysine-core peptide architecture that presents multiple peptide arms from one synthetic construct. Classical MAP systems commonly contain two, four or eight terminal peptide arms—described as MAP2, MAP4 and MAP8—although custom valencies and asymmetric designs may also be evaluated.
MAP technology was developed to increase peptide antigen density without requiring a large carrier protein. This can support antibody production, vaccine research, epitope validation and multivalent recognition studies while providing a chemically defined alternative to heterogeneous carrier-protein conjugates. Successful MAP design requires more than selecting the highest valency: epitope length, core architecture, spacer composition, orientation, charge, hydrophobicity, arm accessibility, synthesis feasibility, purification and analytical characterization must be considered together.
Bio-Synthesis provides sequence review, valency selection, spacer and handle engineering, branched solid-phase peptide synthesis, purification and fit-for-purpose analytical characterization for research-stage MAP projects.
Representative MAP2, MAP4 and MAP8 architectures built from branching lysine cores. Peptide-arm geometry is schematic; actual spacer composition, sequence orientation and core design are project specific.
Scientific note: In this page, carrier-free means that the MAP architecture does not require obligatory attachment to a carrier protein such as KLH. It should not be interpreted as a guarantee of immunogenicity or biological performance.
Multiple peptide copies are displayed without obligatory conjugation to a high-molecular-weight carrier protein.
MAP2, MAP4 and MAP8 formats enable deliberate control of terminal epitope copy number.
Multivalent presentation may enhance effective recognition when arm accessibility and spacing are well designed.
Biotin, fluorescent labels, PEG, lipids, click handles and other modifications may be evaluated.
Use this guide as a design starting point. Final architecture should reflect sequence hydrophobicity, epitope length, intended use, purity expectations and analytical feasibility.
Often suitable for long, hydrophobic or aggregation-prone epitopes and for projects that prioritize purification and analytical resolution.
Long or difficult epitopes
Improved arm accessibility
Lower antigen density
Short hydrophilic spacer as needed
MAP4 frequently offers a practical balance between epitope density, solubility, purification and analytical characterization.
General immunogen design
Moderate-to-high display density
Crowding with longer epitopes
Evaluate Ahx, PEG or amino-acid spacers
MAP8 maximizes classical MAP arm count but requires the most careful review of coupling efficiency, aggregation, purification and mass analysis.
High-density presentation
Maximum classical valency
Incomplete extension and aggregation
Controlled loading and spacer engineering
Different peptide sequences can be displayed within one construct when the biological objective justifies branch-specific synthesis and added analytical complexity.
Combined immune or binding functions
Multiple sequences in one construct
Branch-specific heterogeneity
Orthogonal protection or convergent assembly
MAP cores may be combined with labels, PEG, lipids, proteins or other components when attachment site, purification and analytical strategy are defined in advance.
Functionalized MAP reagents
Expanded experimental utility
Conjugation and purification complexity
Reserved orthogonal handle and staged QC
Design principle: begin with the least complex architecture likely to answer the biological question, then add valency or functionality only when it provides a defined experimental advantage.
Higher valency is not automatically better. Increasing arm count can increase steric crowding, reduce epitope accessibility and complicate synthesis or purification. Architecture should be selected according to sequence behavior and intended use.
MAP peptides are one member of a broader peptide-architecture family. The distinction is primarily architectural and functional—not simply a difference in terminology.
MAP constructs are fully synthetic and have a designed number of peptide arms. Carrier-protein conjugates such as KLH–peptide conjugates contain a distribution of loading levels and attachment sites. Carrier conjugates may still be preferable when the peptide sequence is too difficult for direct multibranch synthesis or when a conventional immunization strategy is required.
A MAP may not be the best choice when native protein folding is essential, very high analytical purity is required for a difficult sequence, independent presentation of several unrelated epitopes is needed, or multifunctional targeting and payload delivery dominate the project.
MAP peptide manufacturing succeeds when architecture, sequence risk, spacer design, purification and analytical strategy are considered together—not as separate afterthoughts.
Assess hydrophobicity, aggregation risk, oxidation and difficult residues.
Select MAP2, MAP4, MAP8 or a custom branched core based on the application.
Balance epitope exposure, flexibility and branch accessibility.
Position labels, biotin, click handles or cleavable elements deliberately.
Match preparative strategy to size, charge, hydrophobicity and heterogeneity.
Define identity, purity and fit-for-purpose characterization requirements.
Common modifications are grouped by design purpose so they read as project specifications—not selectable controls.
FITC, Cy3, Cy5, Alexa Fluor™ dyes and selected FRET pairs.
Biotin, azide, alkyne, DBCO, amino and thiol handles.
Ahx, PEG spacers, flexible linkers and selected cleavable linkers.
Stable isotopes, phosphorylation, glycosylation and custom post-translational modifications.
Design review: Modification placement can affect epitope accessibility, solubility, purification and analytical behavior. Final placement should be reviewed with the complete MAP architecture.
MAP constructs support research programs that benefit from controlled multivalent presentation, carrier-free antigen formats or defined functionalization.
Branched MAP products require a release strategy matched to architecture, molecular weight and expected heterogeneity. The workflow below shows a typical sequence; exact methods are selected project by project.
Controlled branch assembly
Preparative HPLC or tailored method
Identity by MS where technically appropriate
Purity and profile review
Architecture-aware interpretation
Fit-for-purpose documentation
Characterization note: Highly branched constructs may produce broader or more complex analytical profiles than linear peptides. Acceptance criteria should therefore be defined according to the architecture and intended research use.
Explore the progression from standard custom synthesis to increasingly integrated peptide architectures.
Linear, modified and complex custom peptides.
↗
Multi-arm architectures built from defined branch points.
Repeated ligands or epitopes for controlled avidity.
Multiple distinct antigenic sequences in one construct.
Higher-order branched scaffolds with controlled valency.
Dual-target constructs for coordinated recognition.
Scientists ordering MAP constructs frequently combine these services to support labeling, conjugation, immunization studies or expanded release testing.
Our scientists review sequence risk, core architecture, terminal valency, epitope accessibility, spacer design, synthesis feasibility, purification strategy, analytical characterization and scale-up considerations.
Custom MAP2, MAP4, MAP8 and advanced branched peptide constructs supported by controlled synthesis, purification, analytical characterization, documentation and project-specific packaging.
Selected foundational and review articles on the multiple antigen peptide system, synthetic peptide immunogens and lysine-based dendritic peptide architectures.
Editorial note: The historical literature often uses the term multiple antigenic peptide, whereas service pages commonly use Multiple Antigen Peptide. Both refer to the MAP concept; this page uses the latter consistently for navigation and service naming.
Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.